Kalos develops drugs based on short amino acids, creating therapeutic approaches for unmet and rare medical conditions. This technology adapts the mechanisms that limit and control the heart's remodeling to contain and slow the growth of tumors. Our business objective is to out-license technology using an orchestrator trade model to lower drug development costs by 35%. Kalos is 18-24 mos. from revenue with six catalyst licensing events by 2024.